Home / Health / Abivax Drug Shows Promise in Tough Ulcerative Colitis Cases
Abivax Drug Shows Promise in Tough Ulcerative Colitis Cases
30 Jun
Summary
- Experimental ulcerative colitis drug achieved remission in hard-to-treat patients.
- 37.2% of non-responders achieved clinical remission at week 44.
- Cancer rates in expanded safety data align with normal ulcerative colitis patient rates.
Abivax announced that its experimental drug, obefazimod, has demonstrated effectiveness in treating ulcerative colitis, especially in patients with more challenging conditions. For those who initially did not respond to treatment, continuing with obefazimod at a 50 mg dose led to clinical remission in 37.2% of patients and endoscopic remission in 34.5% by week 44.
Furthermore, when patients relapsed during the maintenance phase, increasing the dosage to 50 mg helped 45.5% regain clinical remission. These findings follow earlier trial results where a 25 mg or 50 mg dose achieved clinical remission in over 50% of patients. Concerns about cancer cases, previously noted with the higher dose, appear to be mitigated by expanded safety data. This data, spanning 1,704 patient-years, suggests cancer incidence is consistent with the general ulcerative colitis patient population.
Obefazimod is an orally administered miR-124 enhancer designed to regulate inflammatory responses. Abivax intends to submit a U.S. marketing application for the drug in late 2026.
